L’infection à Mycobacterium ulcerans ou ulcère de Buruli

Röltgen, 2019, Buruli ulcer: history and disease burden [Internet] MacCallum, 1948, A new mycobacterial infection in man, J Pathol Bacteriol, 60, 93, 10.1002/path.1700600111 Lunn, 1965, Buruli (mycobacterial) ulceration in Uganda. (a new focus of Buruli ulcer in Madi district, Uganda): report of a field study, East Afr Med J, 42, 275 O’Brien, 2018, The changing epidemiology worldwide of Mycobacterium ulcerans, Epidemiol Infect [Internet], 147, e19, 10.1017/S0950268818002662 Simpson, 2019, Mapping the global distribution of Buruli ulcer: a systematic review with evidence consensus, Lancet Glob Health [Internet], 7, e912, 10.1016/S2214-109X(19)30171-8 Eddyani, 2018, Diagnostic accuracy of clinical and microbiological signs in patients with skin lesions resembling Buruli ulcer in an endemic region, Clin Infect Dis [Internet], 67, 827, 10.1093/cid/ciy197 Johnson, 2019 Ohtsuka, 2014, Buruli ulcer caused by Mycobacterium ulcerans subsp. shinshuense, JAMA Dermatol [Internet], 150, 64, 10.1001/jamadermatol.2013.6816 Tabah, 2019 Zingue, 2018, Buruli ulcer, a prototype for ecosystem-related infection, caused by Mycobacterium ulcerans, Clin Microbiol Rev [Internet], 31 Loftus, 2018, The incubation period of Buruli ulcer (Mycobacterium ulcerans infection) in Victoria, Australia remains similar despite changing geographic distribution of disease, PLoS Negl Trop Dis [Internet], 12, e0006323, 10.1371/journal.pntd.0006323 Calonge, 2021, Reconstructive surgery for sequellae of Mycobacterium ulcerans infection (Buruli ulcer) of the upper limb, J Plast Surg Hand Surg [Internet], 55, 339, 10.1080/2000656X.2021.1884083 Aubry, 2017, Mycobacterium marinum, Microbiol Spectr [Internet], 10.1128/microbiolspec.TNMI7-0038-2016 Doig, 2012, On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer, BMC Genomics [Internet], 13, 258, 10.1186/1471-2164-13-258 Stinear, 2005, Functional analysis and annotation of the virulence plasmid pMUM001 from Mycobacterium ulcerans, Microbiology (N Y) [Internet], 151, 683 Guenin-Macé, 2019, Mycolactone: more than just a cytotoxin [Internet] George, 2000, A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells, Infect Immun [Internet], 68, 877, 10.1128/IAI.68.2.877-883.2000 Coutanceau, 2005, Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin, Cell Microbiol [Internet], 7, 1187, 10.1111/j.1462-5822.2005.00546.x Strong, 2022, Induced synthesis of mycolactone restores the pathogenesis of Mycobacterium ulcerans in vitro and in vivo, Front Immunol [Internet], 13, 1052 Demangel, 2021, Immunity against Mycobacterium ulcerans: The subversive role of mycolactone, Immunol Rev [Internet], 301, 209, 10.1111/imr.12956 Song, 2017, A bacterial toxin with analgesic properties: hyperpolarization of DRG neurons by mycolactone, Toxins (Basel) [Internet], 9, 227, 10.3390/toxins9070227 Käser, 2007, Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans, BMC Evol Biol [Internet], 7, 177, 10.1186/1471-2148-7-177 Ross, 1997, Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease, Appl Environ Microbiol [Internet], 63, 4135, 10.1128/aem.63.10.4135-4138.1997 Dhungel, 2021, Linking the Mycobacterium ulcerans environment to Buruli ulcer disease: Progress and challenges, One Health [Internet], 13, 100311, 10.1016/j.onehlt.2021.100311 Marion, 2010, Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors, PLoS Negl Trop Dis [Internet], 4, e731, 10.1371/journal.pntd.0000731 Marsollier, 2002, Aquatic insects as a vector for Mycobacterium ulcerans, Appl Environ Microbiol [Internet], 68, 4623, 10.1128/AEM.68.9.4623-4628.2002 Johnson, 2007, Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, Southeastern Australia, Emerg Infect Dis [Internet], 13, 1653, 10.3201/eid1311.061369 Wallace, 2010, Interaction of Mycobacterium ulcerans with mosquito species: implications for transmission and trophic relationships, Appl Environ Microbiol [Internet], 76, 6215, 10.1128/AEM.00340-10 O’Brien, 2014, Clinical, microbiological and pathological findings of Mycobacterium ulcerans infection in three Australian possum species, PLoS Negl Trop Dis [Internet], 8, e2666, 10.1371/journal.pntd.0002666 Röltgen, 2017, Mycobacterium ulcerans DNA in bandicoot excreta in Buruli ulcer – endemic area, Northern Queensland, Australia, Emerg Infect Dis [Internet], 23, 2042, 10.3201/eid2312.170780 Lavender, 2008, Evaluation of VNTR typing for the identification of Mycobacterium ulcerans in environmental samples from Victoria, Australia, FEMS Microbiol Lett [Internet], 287, 250, 10.1111/j.1574-6968.2008.01328.x Narh, 2015, Source tracking Mycobacterium ulcerans infections in the Ashanti region, Ghana, PLoS Negl Trop Dis [Internet], 9, e0003437, 10.1371/journal.pntd.0003437 Muleta, 2021, Understanding the transmission of Mycobacterium ulcerans: A step towards controlling Buruli ulcer, PLoS Negl Trop Dis [Internet], 15, e0009678, 10.1371/journal.pntd.0009678 Wallace, 2017, Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer, PLoS Negl Trop Dis [Internet], 11, e0005553, 10.1371/journal.pntd.0005553 Williamson, 2014, Mycobacterium ulcerans fails to infect through skin abrasions in a guinea pig infection model: implications for transmission, PLoS Negl Trop Dis [Internet], 8, e2770, 10.1371/journal.pntd.0002770 Azumah, 2017, Experimental demonstration of the possible role of Acanthamoeba polyphaga in the infection and disease progression in Buruli ulcer (BU) using ICR mice, PLoS One [Internet], 12, e0172843, 10.1371/journal.pone.0172843 World Health Organisation, 2014 Fyfe, 2022, 71 Marion, 2022, A combined effort of 11 laboratories in the WHO African region to improve quality of Buruli ulcer PCR diagnosis: the “BU-LABNET”, PLoS Negl Trop Dis [Internet], 16, e0010908, 10.1371/journal.pntd.0010908 Wadagni, 2015, Simple, rapid Mycobacterium ulcerans disease diagnosis from clinical samples by fluorescence of mycolactone on thin layer chromatography, PLoS Negl Trop Dis [Internet], 9, e0004247, 10.1371/journal.pntd.0004247 Amewu, 2022, Evaluation of the fluorescent-thin layer chromatography (f-TLC) for the diagnosis of Buruli ulcer disease in Ghana, PLoS One [Internet], 17, e0270235, 10.1371/journal.pone.0270235 Ablordey, 2012, Detection of Mycobacterium ulcerans by the loop mediated isothermal amplification method, PLoS Negl Trop Dis [Internet], 6, e1590, 10.1371/journal.pntd.0001590 Omansen, 2019, Antimicrobial treatment of Mycobacterium ulcerans infection [Internet], 203 O’Brien, 2009, “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure, Med J Aust [Internet], 191, 564, 10.5694/j.1326-5377.2009.tb03313.x Espey, 2002, A pilot study of treatment of Buruli ulcer with rifampin and dapsone, Int J Infect Dis [Internet], 6, 60, 10.1016/S1201-9712(02)90138-4 Meyers, 1974, Heat treatment of Mycobacterium ulcerans infections without surgical excision, Am J Trop Med Hyg [Internet], 23, 924, 10.4269/ajtmh.1974.23.924 Portaels, 1998, In vitro susceptibility of Mycobacterium ulcerans to clarithromycin, Antimicrob Agents Chemother [Internet], 42, 2070, 10.1128/AAC.42.8.2070 Fehr, 1994, Cotrimoxazol in the treatment of Mycobacterium ulcerans infection (Buruli ulcer) in west Africa, Trop Doct [Internet], 24, 61, 10.1177/004947559402400206 Havel, 1975, Activity of rifampicin on Mycobacterium ulcerans, Ann Soc Belg Med Trop, 55, 105 Stanford, 1972, Rifampicin in experimental Mycobacterium ulcerans infection, J Med Microbiol [Internet], 5, 39, 10.1099/00222615-5-1-39 Converse, 2011, Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?, Future Microbiol [Internet], 6, 1185, 10.2217/fmb.11.101 Revill, 1973, A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine, Lancet [Internet], 2, 873, 10.1016/S0140-6736(73)92005-9 Pattyn, 1968, DDS sensitivity of mycobacteria. Antagonistic effect of PABA for M. ulcerans and M. kansasii, Int J Lepr Other Mycobact Dis [Internet], 36, 427 Pattyn, 1965, Traitement de l’infection experimentale de la souris par Mycobacterium ulcerans et Mycobacterium balnei, Ann Soc Belges Med Trop Parasitol Mycol [Internet], 45, 31 Lunn, 1964, Treatment of mycobacterial skin ulcers in Uganda with a riminophenazine derivative (B663), Lancet [Internet], 1, 247, 10.1016/S0140-6736(64)92351-7 Feldman, 1957, Mycobacterium ulcerans infections; response to chemotherapy in mice, Am Rev Tuberc [Internet], 75, 266 Tsouh Fokou, 2016, In vitro activity of selected West African medicinal plants against Mycobacterium ulcerans disease, Molecules, 21, 445, 10.3390/molecules21040445 Ogodo, 2021, Bacteriocidal effects of phytochemicals on Mycobacterium ulcerans, the causative agents of Buruli ulcer [Internet], 337 Vogel, 2016, Local heat application for the treatment of Buruli ulcer: results of a phase II open label single center non-comparative clinical trial, Clin Infect Dis [Internet], 62, 342, 10.1093/cid/civ883 Wadagni, 2018, Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial, Lancet Infect Dis [Internet], 18, 650, 10.1016/S1473-3099(18)30160-9 Velding, 2014, Wound care in Buruli ulcer disease in Ghana and Benin, Am J Trop Med Hyg [Internet], 91, 313, 10.4269/ajtmh.13-0255 Alferink, 2015, Pain associated with wound care treatment among Buruli ulcer patients from Ghana and Benin, PLoS One [Internet], 10, e0119926, 10.1371/journal.pone.0119926 Nwafor, 2019, Assessment of community knowledge, attitude, and stigma of Buruli ulcer disease in Southern Nigeria, Afr Health Sci [Internet], 19, 2100, 10.4314/ahs.v19i2.34 Thangaraj, 2000, In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans, J Antimicrob Chemother, 45, 231, 10.1093/jac/45.2.231 Marsollier, 2003, Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice, Antimicrob Agents Chemother [Internet], 47, 1228, 10.1128/AAC.47.4.1228-1232.2003 Beissner, 2010, A genotypic approach for detection, identification, and characterization of drug resistance in Mycobacterium ulcerans in clinical samples and isolates from Ghana, Am J Trop Med Hyg, 83, 1059, 10.4269/ajtmh.2010.10-0263 Marsollier, 2003, Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin, Int J Antimicrob Agents [Internet], 22, 562, 10.1016/S0924-8579(03)00240-1 Dega, 2002, Bactericidal activity of rifampin–amikacin against Mycobacterium ulcerans in mice, Antimicrob Agents Chemother [Internet], 46, 193 Bentoucha, 2001, Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice, Antimicrob Agents Chemother [Internet], 45, 3109, 10.1128/AAC.45.11.3109-3112.2001 Ji, 2006, In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans, Antimicrob Agents Chemother [Internet], 50, 1921, 10.1128/AAC.00052-06 Ji, 2008, Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice, Antimicrob Agents Chemother [Internet], 52, 1912, 10.1128/AAC.00193-08 Etuaful, 2005, Efficacy of the combination rifampicin–streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans, Antimicrob Agents Chemother [Internet], 49, 3182, 10.1128/AAC.49.8.3182-3186.2005 Chauty, 2007, Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease), Antimicrob Agents Chemother [Internet], 51, 4029, 10.1128/AAC.00175-07 Klis, 2014, Long term streptomycin toxicity in the treatment of Buruli ulcer: follow-up of participants in the BURULICO drug trial, PLoS Negl Trop Dis [Internet], 8, e2739, 10.1371/journal.pntd.0002739 Kibadi, 2007, Les injections répétées de streptomycine dans le traitement de l’infection à Mycobacterium ulcerans (ulcère de Buruli) : à propos d’une enquête dans une zone de santé rurale en République démocratique du Congo, Cah Etud Rech Francoph Sante [Internet], 17, 173 Ji, 2007, Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice, Antimicrob Agents Chemother [Internet], 51, 3737, 10.1128/AAC.00730-07 Nienhuis, 2010, Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial, Lancet [Internet], 375, 664, 10.1016/S0140-6736(09)61962-0 Phillips, 2014, Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease, Antimicrob Agents Chemother, 58, 1161, 10.1128/AAC.02165-13 Dossou, 2008, Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin, Med J Aust [Internet], 189, 532, 10.5694/j.1326-5377.2008.tb02166.x Chauty, 2011, Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin, Clin Infect Dis, 52, 94, 10.1093/cid/ciq072 Phillips, 2020, Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial, Lancet [Internet], 395, 1259, 10.1016/S0140-6736(20)30047-7 Gordon, 2010, All-oral antibiotic treatment for Buruli ulcer: a report of four patients, PLoS Negl Trop Dis [Internet], 4, e770, 10.1371/journal.pntd.0000770 O’Brien, 2014, Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update, Med J Aust [Internet], 200, 267, 10.5694/mja13.11331 O’Brien, 2012, Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study, PLoS Negl Trop Dis [Internet], 6, e1473, 10.1371/journal.pntd.0001473 Yerramilli, 2017, The location of Australian Buruli ulcer lesions — Implications for unravelling disease transmission, PLoS Negl Trop Dis [Internet], 11, e0005800, 10.1371/journal.pntd.0005800 Friedman, 2016, Increasing experience with primary oral medical therapy for Mycobacterium ulcerans disease in an Australian cohort, Antimicrob Agents Chemother [Internet], 60, 2692, 10.1128/AAC.02853-15 Sugawara, 2015, Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan, J Dermatol [Internet], 42, 588, 10.1111/1346-8138.12851 O’Brien, 2020, Six vs. eight weeks of antibiotics for small Mycobacterium ulcerans lesions in Australian patients, Clin Infect Dis [Internet], 70, 1993, 10.1093/cid/ciz532 Boeree, 2017, High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial, Lancet Infect Dis, 17, 39, 10.1016/S1473-3099(16)30274-2 Omansen, 2018, High-dose rifamycins enable shorter oral treatment in a murine model of Mycobacterium ulcerans disease, Antimicrob Agents Chemother [Internet], 63 Amoako, 2022, Buruli-RifDACC: Evaluation of the efficacy and cost-effectiveness of high-dose versus standard-dose rifampicin on outcomes in Mycobacterium ulcerans disease, a protocol for a randomised controlled trial in Ghana [version 1; peer review: 2 approved], NIHR Open Res [Internet], 2, 59, 10.3310/nihropenres.13332.1 Chauffour, 2016, Sterilizing activity of fully oral intermittent regimens against Mycobacterium ulcerans infection in mice, PLoS Negl Trop Dis [Internet], 10, e0005066, 10.1371/journal.pntd.0005066 Converse, 2015, Efficacy of rifampin plus clofazimine in a murine model of Mycobacterium ulcerans disease, PLoS Negl Trop Dis [Internet], 9, e0003823, 10.1371/journal.pntd.0003823 Converse, 2018, Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer, PLoS Negl Trop Dis [Internet], 12, e0006728, 10.1371/journal.pntd.0006728 Chauffour, 2020, Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses, PLoS Negl Trop Dis [Internet], 14, e0007857, 10.1371/journal.pntd.0007857 Komm, 2021, Impact of dose, duration, and immune status on efficacy of ultrashort telacebec regimens in mouse models of Buruli ulcer, Antimicrob Agents Chemother [Internet], 65 Almeida, 2020, Telacebec for ultrashort treatment of Buruli ulcer in a mouse model, Antimicrob Agents Chemother [Internet], 64 N’krumah, 2017, Characteristics and epidemiological profile of Buruli ulcer in the district of Tiassalé, south Côte d’Ivoire, Acta Trop, 175, 138, 10.1016/j.actatropica.2016.12.023 Smithwick, 2016, Landscape fragmentation as a risk factor for Buruli ulcer disease in Ghana, Am J Trop Med Hyg, 95, 63, 10.4269/ajtmh.15-0647 Maman, 2018, Risk factors for Mycobacterium ulcerans infection (Buruli Ulcer) in Togo  a case-control study in Zio and Yoto districts of the maritime region, BMC Infect Dis, 18, 48, 10.1186/s12879-018-2958-3 Nackers, 2007, Environmental and health-related risk factors for Mycobacterium ulcerans disease (Buruli ulcer) in Benin, Am J Trop Med Hyg, 77, 834, 10.4269/ajtmh.2007.77.834 Pouillot, 2007, Risk factors for Buruli ulcer: a case control study in Cameroon, PLoS Negl Trop Dis [Internet], 1, e101, 10.1371/journal.pntd.0000101 Muhi, 2021, Systematic review of M. bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis, Vaccine [Internet], 39, 7238, 10.1016/j.vaccine.2021.05.092